JP2022537385A - 大環状キナーゼ阻害剤の多形 - Google Patents

大環状キナーゼ阻害剤の多形 Download PDF

Info

Publication number
JP2022537385A
JP2022537385A JP2021575515A JP2021575515A JP2022537385A JP 2022537385 A JP2022537385 A JP 2022537385A JP 2021575515 A JP2021575515 A JP 2021575515A JP 2021575515 A JP2021575515 A JP 2021575515A JP 2022537385 A JP2022537385 A JP 2022537385A
Authority
JP
Japan
Prior art keywords
cancer
ret
polymorphic form
diffraction pattern
crystalline
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2021575515A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022537385A5 (cg-RX-API-DMAC7.html
Inventor
デン,ウェイ
ダブリュー ロジャーズ,エバン
ルー,ユエリエ
ジャン,ハン
リウ,ジン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Turning Point Therapeutics Inc
Original Assignee
Turning Point Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Turning Point Therapeutics Inc filed Critical Turning Point Therapeutics Inc
Publication of JP2022537385A publication Critical patent/JP2022537385A/ja
Publication of JP2022537385A5 publication Critical patent/JP2022537385A5/ja
Withdrawn legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains four or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5386—1,4-Oxazines, e.g. morpholine spiro-condensed or forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
JP2021575515A 2019-06-19 2020-06-16 大環状キナーゼ阻害剤の多形 Withdrawn JP2022537385A (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201962863493P 2019-06-19 2019-06-19
US62/863,493 2019-06-19
US202062959940P 2020-01-11 2020-01-11
US62/959,940 2020-01-11
US202063036102P 2020-06-08 2020-06-08
US63/036,102 2020-06-08
PCT/US2020/037892 WO2020257169A1 (en) 2019-06-19 2020-06-16 Polymorphs of a macrocyclic kinase inhibitor

Publications (2)

Publication Number Publication Date
JP2022537385A true JP2022537385A (ja) 2022-08-25
JP2022537385A5 JP2022537385A5 (cg-RX-API-DMAC7.html) 2023-06-26

Family

ID=74040102

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021575515A Withdrawn JP2022537385A (ja) 2019-06-19 2020-06-16 大環状キナーゼ阻害剤の多形

Country Status (15)

Country Link
US (1) US20220411439A1 (cg-RX-API-DMAC7.html)
EP (1) EP3986413A4 (cg-RX-API-DMAC7.html)
JP (1) JP2022537385A (cg-RX-API-DMAC7.html)
KR (1) KR20220046549A (cg-RX-API-DMAC7.html)
CN (1) CN114025765A (cg-RX-API-DMAC7.html)
AU (1) AU2020294627A1 (cg-RX-API-DMAC7.html)
BR (1) BR112021025786A2 (cg-RX-API-DMAC7.html)
CA (1) CA3143043A1 (cg-RX-API-DMAC7.html)
CO (1) CO2022000405A2 (cg-RX-API-DMAC7.html)
IL (1) IL288982A (cg-RX-API-DMAC7.html)
MX (1) MX2021015756A (cg-RX-API-DMAC7.html)
PE (1) PE20220135A1 (cg-RX-API-DMAC7.html)
PH (1) PH12021553174A1 (cg-RX-API-DMAC7.html)
TW (1) TW202115090A (cg-RX-API-DMAC7.html)
WO (1) WO2020257169A1 (cg-RX-API-DMAC7.html)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113336774B (zh) * 2021-06-25 2023-05-23 江南大学 作为trk抑制剂的取代的手性二芳基大环化合物

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015112806A2 (en) * 2014-01-24 2015-07-30 Tp Therapeutics, Inc. Diaryl macrocycles as modulators of protein kinases
RU2732405C2 (ru) * 2015-07-02 2020-09-16 Тёрнинг Поинт Терапьютикс, Инк. Хиральные диарильные макроциклы в качестве модуляторов протеинкиназ
BR112018000297A2 (pt) * 2015-07-06 2018-09-04 Tp Therapeutics Inc polimorfo de macrociclo de diarila
WO2017015367A1 (en) * 2015-07-21 2017-01-26 Tp Therapeutics, Inc. Chiral diaryl macrocycles and uses thereof
CA3069554A1 (en) * 2017-07-14 2019-01-17 Glaxosmithkline Intellectual Property Development Limited Inhibitors of leucine rich repeat kinase 2
RS63787B1 (sr) * 2017-12-19 2022-12-30 Turning Point Therapeutics Inc Makrociklična jedinjenja za lečenje bolesti

Also Published As

Publication number Publication date
PH12021553174A1 (en) 2022-08-01
WO2020257169A1 (en) 2020-12-24
MX2021015756A (es) 2022-01-27
AU2020294627A1 (en) 2022-02-17
IL288982A (en) 2022-02-01
PE20220135A1 (es) 2022-01-27
BR112021025786A2 (pt) 2022-02-01
KR20220046549A (ko) 2022-04-14
CA3143043A1 (en) 2020-12-24
TW202115090A (zh) 2021-04-16
EP3986413A4 (en) 2023-06-14
CN114025765A (zh) 2022-02-08
CO2022000405A2 (es) 2022-04-29
US20220411439A1 (en) 2022-12-29
EP3986413A1 (en) 2022-04-27

Similar Documents

Publication Publication Date Title
JP7212713B2 (ja) ジアリール大環状多形
JP7760493B2 (ja) Rip1阻害化合物ならびにそれを作製および使用するための方法
JP2019518776A (ja) Egfr阻害剤としてのアニリンピリミジン化合物の結晶
US20170226083A1 (en) Forms and compositions of an erk inhibitor
CN1608062A (zh) E-2-甲氧基-n-(3-{4-[3-甲基-4-(6-甲基-吡啶-3-基氧基) -苯氨基]-喹唑啉-6基}-烯丙基)-乙酰胺的盐,其制备和抗癌用途
WO2012136099A1 (zh) 4-(取代苯氨基)喹唑啉衍生物及其制备方法、药物组合物和用途
JP2013526590A (ja) 縮環キナゾリン誘導体及びその使用
WO2013062945A1 (en) Chemical compounds
US20220411439A1 (en) Polymorphs of a macrocyclic kinase inhibitor
CN110283174B (zh) 一类PI3Kδ抑制剂及其用途
JP2006512355A (ja) E−2−メトキシ−n−(3−{4−[3−メチル−4−(6−メチルピリジン−3−イルオキシ)−フェニルアミノ]−キナゾリン−6−イル}−アリル)−アセトアミドの複合体、それらの製造方法および使用
HK40059224A (en) Diaryl macrocycle polymorph and method for preparing the same
HK40059224B (en) Diaryl macrocycle polymorph and method for preparing the same
HK1254492B (en) Diaryl macrocycle polymorph
ZA200502510B (en) Oxygenate treatment of dewaxing catalyst for greatyield of dewaxed product.

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230615

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20230615

A761 Written withdrawal of application

Free format text: JAPANESE INTERMEDIATE CODE: A761

Effective date: 20240105